Vantive brand to be unveiled at 7th CIIE

Baxter's Kidney Care segment, which includes the kidney care and acute therapies businesses, is preparing to become a standalone private company named Vantive. It will be unveiled at the seventh China International Import Expo in Shanghai from Nov 5 to 10.

Building on Baxter's 70-year legacy as a kidney care leader, Vantive will be a new vital organ therapies company. With the mission of "Extending lives, Expanding possibilities," Vantive will showcase its practices in the fields of kidney care and acute critical care at the upcoming CIIE, dedicated to advancing cutting-edge therapies, digital solutions and excellent services to benefit more end-stage kidney disease and acute illness patients. This embodies a localized strategy of "In China, for China," consistently fulfilling its long-term commitment to China's healthcare industry and patient well-being.

"We are grateful for the opportunity to unveil our new Vantive brand alongside other global companies and industry leaders at the most important international trade event in China, which signifies collaboration and a shared commitment to improving health and prosperity," said Chris Toth, executive vice-president and group president of Kidney Care at Baxter, future CEO of Vantive.

He added that the event serves as a key platform for the company to connect with stakeholders, showcase innovative products and services, and work with local clinicians to bring innovation to China and expand access to quality therapies.

As a stand-alone company, Vantive will deepen its commitment to elevating the dialysis experience through digital solutions and advanced services while evolving organ support therapies to go beyond kidney care.

Vital organ therapy innovation

"At this year's CIIE, we are proud to showcase our continued investment in innovation to deliver meaningful breakthroughs for vital organ support therapy," Toth said.

China, like many nations, is facing increasingly complex chronic disorders and an aging population. Better care is possible when clinicians have the right tools to intelligently manage, monitor and optimize therapy administration, Toth said.

He noted that from clinicians fighting to save lives in the intensive care unit to patients on their dialysis journeys, confidence in the solutions supporting each patient's care is critical.

PrisMax, a groundbreaking product with locally manufactured version, will be shown at CIIE. It is designed to improve the safety & efficacy of treatment and lessen the burden to clinicians administering therapy for life-threatening illnesses and complications in the intensive care unit, with its precise, intelligent and convenient functionalities.

In the ICU, CRRT is used to support kidney function while the kidneys recover and is associated with more favorable results compared with intermittent hemodialysis.

"Our continually evolving PrisMax system can manage acute kidney injury, potentially manage sepsis, and acute respiratory distress syndrome, and deliver treatment for autoimmune disorders simultaneously," Toth said.

Top-notch digital products, services

Digital solutions and advanced services are key to achieve Vantive's mission of "Extending Lives, Expanding Possibilities". By enabling greater connection, visibility and insights throughout the care journey, Vantive can create new opportunities for clinicians to make timely adjustments to care or intervene earlier to address a patient's needs.

At the CIIE, Vantive will demonstrate its innovation in digital technology to intelligently manage, monitor and optimize therapy.

For example, its digital solutions — such as MyPD and Sharesource remote patient management platforms for home dialysis —empower patients to better understand their therapy while staying connected to their clinical team. And to ensure HCP to intelligently manage, monitor and optimize therapy administration. Vantive also introduces automated peritoneal dialysis for patients at home, as well as advanced hemodialysis.

"As a local manufacturer of technologies that support home dialysis, we will also be announcing several major agreements with local partners to further our investment and continued presence in China," Toth said.

Expanded access to care

Vantive's other key focus is expanded access to care. Vantive's therapies meet patients wherever they are, including at home, and Vantive is committed to breaking down the barriers to care through partnerships and awareness-raising initiatives, greater connection and support throughout the care journey and a focus on clinical evidence generation.

At the CIIE, Vantive will display innovations in home dialysis, which includes digital products and services to keep patients and clinicians connected.

Commitment to China market

Baxter's Kidney Care segment, soon to be Vantive, has been deeply rooted in the Chinese market for more than 35 years and has achieved many remarkable milestones in manufacturing, medical innovation and partnerships with local clinicians.

Vantive China boasts a world-class research and development center in Suzhou city, Jiangsu province, a technical service center in Shanghai, and three manufacturing facilities in Tianjin, Guangzhou and Suzhou cities.

"To support patients and clinicians in China we are continuing to increase our investment in the local healthcare system in areas that will make a significant impact for patients and their care teams," Toth said.

"We are proud to bring remote patient management technology to support patients on home dialysis, and cutting edge innovation to the ICU with our local made PrisMax system. At Vantive, our diverse R&D team of scientists and engineers is spearheading these initiatives, while we are also investing in external research collaborations," he said.

Toth noted that this includes collaboration with local governments to increase access to innovative therapies and home-based dialysis to create a sustainable healthcare system now and into the future.

"Looking ahead, we will continue to deepen our investment in China, support local innovation, and maintain close cooperation with Chinese regulatory authorities and partners. Through our collective efforts, we can ensure that patients in China and around the world benefit from the latest medical innovations," he said.